Jaroslaw P. Maciejewski

Cleveland Clinic — United States

Medicine · Health Sciences

105h-index42.8kcitations1.5kworks3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(845), Myeloproliferative Neoplasms: Diagnosis and Treatment(318), Chronic Myeloid Leukemia Treatments(189), Chronic Lymphocytic Leukemia Research(162), Hematopoietic Stem Cell Transplantation(133)

Publications1.5k total

DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study
Leukemia·2025· 2 cited
Molecular Insights and Therapeutic Advances in Low-Risk Myelodysplastic Neoplasms: A Clinical Review
Cancers·2025· 2 citedOpen Access
First-in-human evaluation of IL2RG blockade in patients with severe aplastic anemia that is refractory to or relapsed on immunosuppressive therapy
Blood·2025
Real-world breakthrough hemolysis patterns across 1,723 patient-years of complement inhibition in paroxysmal nocturnal hemoglobinuria
Blood·2025Open Access
Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database
Blood·2025Open Access
GLP‑1 receptor agonists and clonal hematopoiesis: Early human signals of anti‑inflammatory clone mitigation and lower MDS‑to‑AML progression
Blood·2025
Serum ferritin changes in iptacopan-treated patients with paroxysmal nocturnal hemoglobinuria
Blood·2025
An integrative prognostic model for transplant outcomes in myelofibrosis
Blood·2025
Which molecular patterns of high-risk myeloid malignancies are concordantly identified using two machine learning algorithms?
Blood·2025
Machine learning uncovers invariant evolutionary molecular trajectories in MDS.
Blood·2025Open Access
The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome
Blood·2025
C-CBL mutations affecting residue 371 confer dismal prognosis in MDS and CMML
Blood·2025Open Access
A pilot study of nicotinamide riboside supplementation in allogeneic bone marrow transplantation
Blood·2025Open Access
Germline alterations of hematopoietic growth factor receptors and maladaptive somatic genetic rescue leads to myeloid neoplasia
Blood·2025
Multi‑omics analysis of Del20q reveals PHF20 haploinsufficiency and an HDAC2-centered epigenetic circuit in myeloid neoplasms
Blood·2025Open Access
The basis for the differential impact of BCOR and BCORL1 in aplastic anemia/paroxysmal nocturnal hemoglobinuria and myeloid neoplasia
Blood·2025
Prognostic impact of pre-transplant IPSS-m risk downstaging in Myelodysplastic Syndromes
Blood·2025
Invariant patterns of global mutational signatures allow new fundamental insights in etiopathogenesis of bone marrow failure including aplastic anemia and myelodysplasia
Blood·2025Open Access
Serum erythropoietin level as a selective pressure in clonal hematopoiesis: Insights into the mutational landscape of myeloid neoplasias
Blood·2025Open Access
Novel approaches to identify cellular vulnerabilities in TET2-dependent MDS
Blood·2025Open Access
page 1 of 76Next →

Frequent Co-authors

Mikkael A. Sekeres(19), Hideki Makishima(14), Neal S. Young(11), Alan F. List(9), Ramón V. Tiu(9), Seishi Ogawa(8), Christine L. O’Keefe(8), Kenichi Yoshida(7), Bartlomiej Przychodzen(7), Hadrian Szpurka(7), Michael A. McDevitt(7), Yuichi Shiraishi(6), Kenichi Chiba(6), Hiroko Tanaka(6), Satoru Miyano(6), Andrés Jerez(6), Luca Malcovati(5), Mario Cazzola(5), Antonio M. Risitano(5), Michael J. Clemente(5)